A.forall and its US subsidiary Milla Pharmaceuticals have announced the approval and launch of their generic tromethamine injection while also securing the coveted Competitive Generic Therapy 180-day exclusivity in process.
A.forall Launches Generic Tromethamine With 180-Day US Exclusivity
Launch Marks The Second A.forall Product With The Coveted CGT Designation
The commercialization of the generic version of Hospira’s THAM solution will be carried out by A.forall’s US subsidiary Milla Pharmaceuticals.
